Community Health Systems, Inc. Announces First Quarter Ended March 31, 2022 Results

FRANKLIN, Tenn.–(BUSINESS WIRE)–Community Health Systems, Inc. (NYSE: CYH) (the “Company”) today announced financial and operating results for the three months ended March 31, 2022.

The following highlights the financial and operating results for the three months ended March 31, 2022.

  • Net operating revenues totaled $3.111 billion.
  • Net loss attributable to Community Health Systems, Inc. stockholders was $(1) million, or $(0.01) per share (diluted), compared to $(64) million, or $(0.51) per share (diluted), for the same period in 2021. Excluding the adjusting items as presented in the table in footnote (e) on page 12, net income attributable to Community Health Systems, Inc. stockholders was $0.14 per share (diluted), compared to $0.36 per share (diluted) for the same period in 2021.
  • Adjusted EBITDA was $409 million, including $47 million of pandemic relief funds.
  • Net cash provided by operating activities was $101 million for both of the three-month periods ended March 31, 2022 and 2021.
  • On a same-store basis, admissions decreased 0.3 percent and adjusted admissions increased 3.2 percent, compared with the same period in 2021.

Net operating revenues for the three months ended March 31, 2022, totaled $3.111 billion, a 3.3 percent increase compared with $3.013 billion for the same period in 2021.

Net loss attributable to Community Health Systems, Inc. stockholders was $(1) million, or $(0.01) per share (diluted), for the three months ended March 31, 2022, compared to $(64) million, or $(0.51) per share (diluted), for the same period in 2021. Excluding the adjusting items as presented in the table in footnote (e) on page 12, net income attributable to Community Health Systems, Inc. stockholders was $0.14 per share (diluted) for the three months ended March 31, 2022, compared to $0.36 per share (diluted) for the same period in 2021. Pandemic relief funds, as more specifically described below, had a positive impact on net loss attributable to Community Health Systems, Inc. stockholders (both on a consolidated and adjusted basis) of approximately $35 million, or $0.27 on a per share (diluted) basis, and approximately $62 million, or $0.54 on a per share (diluted) basis, for the three months ended March 31, 2022 and 2021, respectively. Weighted-average shares outstanding (diluted) were 128 million and 126 million for the three months ended March 31, 2022 and 2021, respectively.

Adjusted EBITDA for the three months ended March 31, 2022, was $409 million compared with $495 million for the same period in 2021. Pandemic relief funds had a positive impact on Adjusted EBITDA of approximately $47 million and $82 million for the three months ended March 31, 2022 and 2021, respectively.

The consolidated operating results for the three months ended March 31, 2022, reflect a 1.7 percent decrease in admissions and a 2.2 percent increase in adjusted admissions, compared with the same period in 2021. On a same-store basis, admissions decreased 0.3 percent and adjusted admissions increased 3.2 percent for the three months ended March 31, 2022, compared with the same period in 2021. On a same-store basis, net operating revenues increased 3.8 percent for the three months ended March 31, 2022, compared with the same period in 2021.

As a provider of healthcare services, the Company continues to be affected by the public health and economic effects of the COVID-19 pandemic. During the three months ended March 31, 2022 and 2021, the Company received approximately $42 million and $3 million, respectively, in pandemic relief fund payments through various federal, state and local programs. During the three months ended March 31, 2022 and 2021, the Company recognized approximately $47 million and $82 million, respectively, of the pandemic relief funds eligible to be claimed as a reduction in operating costs and expenses. Amounts recognized are denoted by the caption “pandemic relief funds” in the condensed consolidated statements of loss. Pandemic relief funds that have not yet been recognized as a reduction in operating costs and expenses or otherwise refunded to the U.S. Department of Health and Human Services or the various state and local agencies as of March 31, 2022, totaled approximately $9 million and are reflected within accrued liabilities-other in the condensed consolidated balance sheet.

Commenting on the results, Tim L. Hingtgen, chief executive officer of Community Health Systems, Inc., said, “We experienced the largest COVID surge to date during the first quarter, which negatively impacted net operating revenues, labor expense, and length of stay during the quarter. The Company’s leadership teams and healthcare providers continued their remarkable efforts – providing safe, quality care while at the same time managing through a challenging environment. As COVID case counts subsided, our operational and financial performance significantly improved during the month of March, as patient volumes returned and COVID-related expenses moderated. Moving through the second quarter and the remainder of the year, we anticipate contract labor rates to remain elevated, however, we expect our operational momentum to continue, as we anticipate capturing deferred healthcare demand, benefitting from recent strategic investments, and continuing the execution of the Company’s margin improvement program.”

Financial and statistical data for 2022 and 2021 presented in this press release includes the operating results of divested or closed businesses for the periods prior to the consummation of the respective divestiture or closing. Same-store operating results exclude businesses divested or closed in 2021.

Information About Non-GAAP Financial Measures

This press release presents Adjusted EBITDA, a non-GAAP financial measure, which is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, gain on sale of equity interests in Macon Healthcare, LLC, expense incurred in the fourth quarter of 2020 related to the settlement of certain professional liability claims for which the third-party insurers’ obligation to insure the Company against the underlying loss was being litigated along with income during the fourth quarter of 2021 associated with the settlement of such litigation for the recovery of amounts covered by such third-party insurance policies, expense related to employee termination benefits and other restructuring charges, and expense from settlement and fair value adjustments on the contingent value right agreement liability related to the Health Management Associates, Inc. (“HMA”) legal proceedings and related legal expenses. For information regarding why the Company believes Adjusted EBITDA provides useful information to investors, and for a reconciliation of Adjusted EBITDA to net loss attributable to Community Health Systems, Inc. stockholders, see footnote (c) to the Financial Highlights, Financial Statements and Selected Operating Data below.

Additionally, this press release presents adjusted net income attributable to Community Health Systems, Inc. stockholders per share (diluted), a non-GAAP financial measure, to reflect the impact on net loss attributable to Community Health Systems, Inc. stockholders per share (diluted) from the selected items used in the calculation of Adjusted EBITDA. For information regarding why the Company believes this non-GAAP financial measure provides useful information to investors, and for a reconciliation of this non-GAAP financial measure to net loss attributable to Community Health Systems, Inc. stockholders per share (diluted), see footnote (e) to the Financial Highlights, Financial Statements and Selected Operating Data below.

The non-GAAP financial measures set forth above are not measurements of financial performance under U.S. GAAP, and should not be considered in isolation or as a substitute for any financial measure calculated in accordance with U.S. GAAP. Additionally, the calculation of these non-GAAP financial measures may not be comparable to similarly titled measures disclosed by other companies.

Included on pages 13, 14, 15, 16 and 17 of this press release are tables setting forth the Company’s 2022 updated annual earnings guidance. The 2022 guidance is based on the Company’s historical operating performance, current trends and other assumptions that the Company believes are reasonable at this time as more specifically discussed below.

Community Health Systems, Inc. is one of the largest publicly traded providers of healthcare services in the United States and a leading operator of general acute care hospitals and outpatient facilities in communities across the country. The Company, through its subsidiaries, owns or leases 83 affiliated hospitals in 16 states with an aggregate of approximately 13,000 licensed beds.

The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.

Community Health Systems, Inc. will hold a conference call on Thursday, April 28, 2022, at 10:00 a.m. Central, 11:00 a.m. Eastern, to review financial and operating results for the first quarter ended March 31, 2022. Investors will have the opportunity to listen to a live internet broadcast of the conference call by clicking on the Investor Relations link of the Company’s website at www.chs.net. For those who cannot listen to the live broadcast, a replay will be available shortly after the call and will continue to be available for approximately 30 days. Copies of this press release and conference call slide show, as well as the Company’s Current Report on Form 8-K (including this press release), will be available on the Company’s website at www.chs.net.

 
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES
Financial Highlights (a)(b)
(In millions, except per share amounts)
(Unaudited)
 
 
Three Months Ended
March 31,

2022

2021

 
Net operating revenues $

3,111

 

$

3,013

 

Net income (loss) (f)

30

 

(35

)

Net loss attributable to Community Health
Systems, Inc. stockholders

(1

)

(64

)

Adjusted EBITDA (c)

409

 

495

 

Net cash provided by operating activities

101

 

101

 

 
Loss per share attributable to Community
Health Systems, Inc. stockholders:
Basic (f) $

(0.01

)

$

(0.51

)

Diluted (e), (f)

(0.01

)

(0.51

)

 
Weighted-average number of shares outstanding (d):
Basic

128

 

126

 

Diluted

128

 

126

 

 

____

For footnotes, see pages 10, 11 and 12.

 
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Loss (a)(b)
(In millions, except per share amounts)
(Unaudited)
 
Three Months Ended March 31,

2022

2021

% of Net % of Net
Operating Operating
Amount Revenues Amount Revenues
Net operating revenues $

3,111

 

100.0

 

%

$

3,013

 

100.0

 

%

 
Operating costs and expenses:
Salaries and benefits

1,325

 

42.6

 

%

1,303

 

43.2

 

%

Supplies

499

 

16.0

 

%

491

 

16.3

 

%

Other operating expenses

853

 

27.4

 

%

738

 

24.5

 

%

Lease cost and rent

77

 

2.5

 

%

78

 

2.6

 

%

Pandemic relief funds

(47

)

(1.5

)

%

(82

)

(2.7

)

%

Depreciation and amortization

128

 

4.1

 

%

138

 

4.6

 

%

Impairment and (gain) loss on sale of businesses, net (f)

6

 

0.2

 

%

21

 

0.7

 

%

Total operating costs and expenses

2,841

 

91.3

 

%

2,687

 

89.2

 

%

 
Income from operations (f)

270

 

8.7

 

%

326

 

10.8

 

%

Interest expense, net

217

 

7.0

 

%

231

 

7.7

 

%

Loss from early extinguishment of debt

5

 

0.2

 

%

71

 

2.3

 

%

Equity in earnings of unconsolidated affiliates

(5

)

(0.2

)

%

(10

)

(0.3

)

%

 
Income before income taxes

53

 

1.7

 

%

34

 

1.1

 

%

Provision for income taxes

23

 

0.7

 

%

69

 

2.3

 

%

Net income (loss) (f)

30

 

1.0

 

%

(35

)

(1.2

)

%

Less: Net income attributable to noncontrolling interests

31

 

1.0

 

%

29

 

0.9

 

%

Net loss attributable to Community Health Systems,
Inc. stockholders $

(1

)

0.0

 

%

$

(64

)

(2.1

)

%

 
Loss per share attributable to Community
Health Systems, Inc. stockholders:
Basic (f) $

(0.01

)

$

(0.51

)

Diluted (e), (f) $

(0.01

)

$

(0.51

)

 
Weighted-average number of shares outstanding (d):
Basic

128

 

126

 

Diluted

128

 

126

 

____

For footnotes, see pages 10, 11 and 12.

 
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Loss
(In millions)
(Unaudited)
 
Three Months Ended
March 31,

2022

2021

 
Net income (loss) $

30

 

$

(35

)

Other comprehensive loss, net of income taxes:
Net change in fair value of available-for-sale debt
securities, net of tax

(8

)

(3

)

Other comprehensive loss

(8

)

(3

)

Comprehensive income (loss)

22

 

(38

)

Less: Comprehensive income attributable to noncontrolling interests

31

 

29

 

Comprehensive loss attributable to Community Health
Systems, Inc. stockholders $

(9

)

$

(67

)

 

____

For footnotes, see pages 10, 11 and 12.

 
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES
Selected Operating Data (a)
(Dollars in millions)
(Unaudited)
 
Three Months Ended March 31,
Consolidated Same-Store

 

2022

 

2021

 

% Change

 

2022

 

2021

 

% Change

Number of hospitals (at end of period)

 

83

 

 

85

 

 

83

 

 

83

 

Licensed beds (at end of period)

 

13,289

 

 

13,563

 

 

13,289

 

 

13,308

 

Beds in service (at end of period)

 

11,557

 

 

11,991

 

 

11,557

 

 

11,736

 

Admissions

 

108,367

 

 

110,268

 

-1.7

%

 

108,367

 

 

108,689

 

-0.3

%

Adjusted admissions

 

232,315

 

 

227,366

 

2.2

%

 

232,290

 

 

224,983

 

3.2

%

Patient days

 

551,245

 

 

549,991

 

 

551,245

 

 

541,541

 

Average length of stay (days)

 

5.1

 

 

5.0

 

 

5.1

 

 

5.0

 

Occupancy rate (average beds in service)

 

53.0

%

 

50.8

%

 

53.0

%

 

51.2

%

Net operating revenues

$

3,111

 

$

3,013

 

3.3

%

$

3,108

 

$

2,995

 

3.8

%

Net inpatient revenues as a % of net operating
revenues

 

49.4

%

 

49.8

%

 

49.4

%

 

49.6

%

Net outpatient revenues as a % of net operating
revenues

 

50.6

%

 

50.2

%

 

50.6

%

 

50.4

%

Income from operations (f)

$

270

 

$

326

 

-17.2

%

Income from operations as a % of net
operating revenues

 

8.7

%

 

10.8

%

Depreciation and amortization

$

128

 

$

138

 

Equity in earnings of unconsolidated affiliates

$

(5

)

$

(10

)

Net loss attributable to Community Health
Systems, Inc. stockholders

$

(1

)

$

(64

)

98.4

%

Net loss attributable to Community Health
Systems, Inc. stockholders as a % of net
operating revenues

 

0.0

%

 

-2.1

%

Adjusted EBITDA (c)

$

409

 

$

495

 

-17.4

%

Adjusted EBITDA as a % of net
operating revenues

 

13.1

%

 

16.4

%

Net cash provided by operating activities

$

101

 

$

101

 

0.0

%

 

____

For footnotes, see pages 10, 11 and 12.

 
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In millions, except share data)
(Unaudited)
March 31, 2022 December 31, 2021
ASSETS
Current assets
Cash and cash equivalents $

460

 

$

507

 

Patient accounts receivable

2,079

 

2,062

 

Supplies

353

 

355

 

Prepaid income taxes

95

 

94

 

Prepaid expenses and taxes

229

 

192

 

Other current assets

272

 

269

 

Total current assets

3,488

 

3,479

 

Property and equipment

9,779

 

9,757

 

Less accumulated depreciation and amortization

(4,223

)

(4,204

)

Property and equipment, net

5,556

 

5,553

 

Goodwill

4,219

 

4,219

 

Deferred income taxes

53

 

53

 

Other assets, net

1,947

 

1,913

 

Total assets $

15,263

 

$

15,217

 

 
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities
Current maturities of long-term debt $

43

 

$

31

 

Current operating lease liabilities

149

 

147

 

Accounts payable

825

 

830

 

Accrued liabilities:
Employee compensation

697

 

655

 

Accrued interest

186

 

225

 

Other

447

 

476

 

Total current liabilities

2,347

 

2,364

 

Long-term debt (g)

12,154

 

12,109

 

Deferred income taxes

213

 

192

 

Long-term operating lease liabilities

578

 

535

 

Other long-term liabilities

790

 

827

 

Total liabilities

16,082

 

16,027

 

Redeemable noncontrolling interests in equity of consolidated subsidiaries

493

 

480

 

STOCKHOLDERS’ DEFICIT
Community Health Systems, Inc. stockholders’ deficit:
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued

 

 

Common stock, $.01 par value per share, 300,000,000 shares authorized; 134,686,087
shares issued and outstanding at March 31, 2022, and 132,146,282 shares
issued and outstanding at December 31, 2021

1

 

1

 

Additional paid-in capital

2,107

 

2,118

 

Accumulated other comprehensive loss

(22

)

(14

)

Accumulated deficit

(3,478

)

(3,477

)

Total Community Health Systems, Inc. stockholders’ deficit

(1,392

)

(1,372

)

Noncontrolling interests in equity of consolidated subsidiaries

80

 

82

 

Total stockholders’ deficit

(1,312

)

(1,290

)

Total liabilities and stockholders’ deficit $

15,263

 

$

15,217

 

 
 

____

For footnotes, see pages 10, 11 and 12.

 
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(In millions)
(Unaudited)
 
Three Months Ended March 31,

2022

2021

 
Cash flows from operating activities
Net income (loss) $

30

 

$

(35

)

Adjustments to reconcile net income (loss) to net cash provided by
operating activities:
Depreciation and amortization

128

 

138

 

Deferred income taxes

22

 

68

 

Stock-based compensation expense

5

 

8

 

Impairment and (gain) loss on sale of businesses, net (f)

6

 

21

 

Loss from early extinguishment of debt

5

 

71

 

Other non-cash expenses, net

45

 

(40

)

Changes in operating assets and liabilities, net of effects of
acquisitions and divestitures:
Patient accounts receivable

(17

)

(34

)

Supplies, prepaid expenses and other current assets

(40

)

(2

)

Repayment/derecognition of Medicare accelerated payments

 

(18

)

Accounts payable, accrued liabilities and income taxes

(23

)

(23

)

Other

(60

)

(53

)

Net cash provided by operating activities

101

 

101

 

 
Cash flows from investing activities
Acquisitions of facilities and other related businesses

(1

)

(4

)

Purchases of property and equipment

(97

)

(105

)

Proceeds from disposition of hospitals and other ancillary operations

2

 

6

 

Proceeds from sale of property and equipment

 

2

 

Purchases of available-for-sale debt securities and equity securities

(31

)

(22

)

Proceeds from sales of available-for-sale debt securities and equity securities

24

 

26

 

Purchases of investments in unconsolidated affiliates

(4

)

 

Increase in other investments

(14

)

(23

)

Net cash used in investing activities

(121

)

(120

)

 
Cash flows from financing activities
Repurchase of restricted stock shares for payroll tax withholding requirements

(8

)

(5

)

Deferred financing costs and other debt-related costs

(73

)

(220

)

Proceeds from noncontrolling investors in joint ventures

1

 

 

Distributions to noncontrolling investors in joint ventures

(29

)

(21

)

Other borrowings

27

 

3

 

Issuance of long-term debt

1,535

 

2,870

 

Repayments of long-term indebtedness

(1,480

)

(3,033

)

Net cash used in financing activities

(27

)

(406

)

 
Net change in cash and cash equivalents

(47

)

(425

)

Cash and cash equivalents at beginning of period

507

 

1,676

 

Cash and cash equivalents at end of period $

460

 

$

1,251

 

 

____

For footnotes, see pages 10, 11 and 12.

Footnotes to Financial Highlights, Financial Statements and Selected Operating Data

(a)

Both financial and statistical results include the operating results of divested or closed businesses for the periods prior to the consummation of the respective divestiture or closing. Same-store operating results and statistical information exclude businesses divested or closed in 2021. There were no discontinued operations reported for 2022 and 2021.

 

(b)

The following table provides information needed to calculate loss per share, which is adjusted for income attributable to noncontrolling interests (in millions):

 
Three Months Ended
March 31,

2022

2021

Net loss attributable to Community Health Systems,
Inc. stockholders:
Net income (loss) $

30

 

$

(35

)

Less: Income attributable to noncontrolling interests, net of taxes

31

 

29

 

Net loss attributable to Community Health Systems,
Inc. stockholders — basic and diluted $

(1

)

$

(64

)

 

(c)

EBITDA is a non-GAAP financial measure which consists of net loss attributable to Community Health Systems, Inc. before interest, income taxes, and depreciation and amortization. Adjusted EBITDA, also a non-GAAP financial measure, is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, gain on sale of equity interests in Macon Healthcare, LLC, expense incurred in the fourth quarter of 2020 related to the settlement of certain professional liability claims for which the third-party insurers’ obligation to insure the Company against the underlying loss was being litigated along with income during the fourth quarter of 2021 associated with the settlement of such litigation for the recovery of amounts covered by such third-party insurance policies, expense related to employee termination benefits and other restructuring charges, and expense from settlement and fair value adjustments on the contingent value right agreement liability related to the HMA legal proceedings and related legal expenses. The Company has from time to time sold noncontrolling interests in certain of its subsidiaries or acquired subsidiaries with existing noncontrolling interest ownership positions. The Company believes that it is useful to present Adjusted EBITDA because it adds back the portion of EBITDA attributable to these third-party interests. The Company reports Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by management to assess the operating performance of the Company’s hospital operations and to make decisions on the allocation of resources. Adjusted EBITDA is also used to evaluate the performance of the Company’s executive management team and is one of the primary metrics used in connection with determining short-term cash incentive compensation and the achievement of vesting criteria with respect to performance-based equity awards. In addition, management utilizes Adjusted EBITDA in assessing the Company’s consolidated results of operations and operational performance and in comparing the Company’s results of operations between periods. The Company believes it is useful to provide investors and other users of the Company’s financial statements this performance measure to align with how management assesses the Company’s results of operations. Adjusted EBITDA also is comparable to a similar metric called Consolidated EBITDA, as defined in the Company’s asset-based loan facility (the “ABL Facility”) and the Company’s existing note indentures, which is a key component in the determination of the Company’s compliance with certain covenants under the ABL Facility and such note indentures (including the Company’s ability to service debt and incur capital expenditures), and is used to determine the interest rate and commitment fee payable under the ABL Facility (although Adjusted EBITDA does not include all of the adjustments described in the ABL Facility). Adjusted EBITDA includes the Adjusted EBITDA attributable to hospitals that were divested during the course of such year, but in each case solely to the extent relating to the period prior to the consummation of the applicable divestiture.

 

Adjusted EBITDA is not a measurement of financial performance under U.S. GAAP. It should not be considered in isolation or as a substitute for net income, operating income, or any other performance measure calculated in accordance with U.S. GAAP. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating financial performance. The Company believes such adjustments are appropriate as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Additionally, this calculation of Adjusted EBITDA may not be comparable to similarly titled measures disclosed by other companies.

 

The following table reflects the reconciliation of Adjusted EBITDA, as defined, to net loss attributable to Community Health Systems, Inc. stockholders as derived directly from the condensed consolidated financial statements (in millions):

 
Three Months Ended
March 31,

2022

2021

Net loss attributable to Community Health
Systems, Inc. stockholders $

(1

)

$

(64

)

Adjustments:
Provision for income taxes

23

 

69

 

Depreciation and amortization

128

 

138

 

Net income attributable to noncontrolling interests

31

 

29

 

Interest expense, net

217

 

231

 

Loss from early extinguishment of debt

5

 

71

 

Impairment and (gain) loss on sale of businesses, net

6

 

21

 

Adjusted EBITDA $

409

 

$

495

 

 

(d)

The following table sets forth components reconciling the basic weighted-average number of shares to the diluted weighted-average number of shares (in millions):

 
Three Months Ended
March 31,

2022

2021

 
Weighted-average number of shares outstanding – basic

128

126

Add effect of dilutive securities:
Stock awards and options

 
Weighted-average number of shares outstanding – diluted

128

126

 

The Company generated a net loss attributable to Community Health Systems, Inc. stockholders for both the three months ended March 31, 2022 and 2021, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated net income, the effect of stock awards and options on the diluted shares calculation would have been an increase of 2,198,436 shares and 2,267,756 shares during the three months ended March 31, 2022 and 2021, respectively.

 

(e)

The following supplemental table reconciles net loss attributable to Community Health Systems, Inc. stockholders, as reported, on a per share (diluted) basis, to net income attributable to Community Health Systems, Inc. stockholders per share (diluted) with the adjustments described herein (total per share amounts may not add due to rounding). The Company believes that the presentation of non-GAAP adjusted net income attributable to Community Health Systems, Inc. stockholders per share (diluted) presents useful information to investors by highlighting the impact on net income attributable to Community Health Systems, Inc. stockholders per share (diluted) of selected items used in calculating Adjusted EBITDA which may not reflect the Company’s underlying operating performance and assisting in comparing the Company’s results of operations between periods.

 
Three Months Ended
March 31,

2022

2021

 
Net loss per share (diluted), as reported

$

(0.01

)

$

(0.51

)

Adjustments:
Loss from early extinguishment of debt

 

0.11

 

 

0.74

 

Impairment and (gain) loss on sale of businesses, net

 

0.04

 

 

0.13

 

Net income per share (diluted), excluding adjustments

$

0.14

 

$

0.36

 

 

(f)

Both income from operations and net income (loss) included a net non-cash expense of $6 million and $21 million for the three months ended March 31, 2022 and 2021, respectively, primarily from impairment charges to reduce the value of certain long-lived assets at businesses the Company identified for sale or sold and gains on the sale of certain businesses during such periods. These impairment charges do not have an impact on the calculation of the Company’s financial covenants under the ABL Facility.

 

 

(g)

The maximum aggregate principal amount under the ABL Facility is $1.0 billion. At March 31, 2022, the available borrowing base under the ABL Facility was $1.0 billion, of which $103 million is reserved for outstanding letters of credit and $897 million represents excess availability. The Company had no outstanding borrowings as of March 31, 2022.

Regulation FD Disclosure

Set forth below is selected information concerning the Company’s projected consolidated operating results for the year ending December 31, 2022. These projections update selected guidance provided on February 16, 2022, and are based on the Company’s historical operating performance, current trends and other assumptions that the Company believes are reasonable at this time. The 2022 guidance should be considered in conjunction with the assumptions included herein. See pages 15, 16 and 17 for a list of factors that could affect the future results of the Company or the healthcare industry generally.

The following is provided as guidance to analysts and investors:

 
2022 Projection Range
Net operating revenues (in millions) $

12,600

to $

13,100

Adjusted EBITDA (in millions) $

1,775

to $

1,925

Net income per share – diluted $

0.75

to $

1.30

Weighted-average diluted shares (in millions)

133.0

to

134.0

 

The following assumptions were used in developing the 2022 guidance provided above:

  • The Company’s projections exclude the following:

    • Effect of debt refinancing activities, including gains and losses from early extinguishment of debt;
    • Impairment of goodwill and long-lived assets;
    • Previously recorded pandemic relief funds and the potential recognition of additional pandemic relief funds;
    • The impact of any potential future divestitures;
    • Gains or losses from the sales of businesses;
    • Employee termination benefits and restructuring costs;
    • Resolution of government investigations or other significant legal settlements;
    • Costs incurred in connection with divestitures; and
    • Other significant gains or losses that neither relate to the ordinary course of business nor reflect the Company’s underlying business performance.

Other assumptions used in the above guidance:

  • Expressed as a percentage of net operating revenues, depreciation and amortization of approximately 4.2% for 2022. Additionally, this is a fixed cost and the percentages may vary based on changes in net operating revenues. Such amounts exclude the possible impact of any future hospital fixed asset impairments.
  • Interest expense is estimated to be between $855 million and $875 million while cash paid for interest, which excludes the amortization of deferred financing costs, is expected to be $820 million to $840 million. Total fixed rate debt is expected to average approximately 100% of total debt during 2022.
  • Expressed as a percentage of net operating revenues, net income attributable to noncontrolling interests of approximately 1.0% for 2022.
  • Expressed as a percentage of net operating revenues, provision for income taxes of approximately 1.2% to 1.6% for 2022.

A reconciliation of the Company’s projected 2022 Adjusted EBITDA, a forward-looking non-GAAP financial measure, to the Company’s projected net income attributable to Community Health Systems, Inc. stockholders, the most directly comparable GAAP financial measure, is shown below:

 
Year Ending
December 31, 2022
Low High
Net income attributable to Community Health Systems, Inc.
stockholders (1) $

100

$

174

Adjustments:
Depreciation and amortization

530

550

Interest expense, net

875

855

Provision for income taxes

145

205

Net income attributable to noncontrolling interests

125

141

Adjusted EBITDA (1) $

1,775

$

1,925

 

(1)

The Company does not include in this reconciliation the impact of certain items not included in the Company’s forecast set forth above that would be included in a reconciliation of historical net income (loss) attributable to Community Health Systems, Inc. stockholders to Adjusted EBITDA such as, but not limited to, losses (gains) from early extinguishment of debt and impairment and (gain) loss on sale of businesses, in light of the fact that such items are not determinable, and/or the inherent difficulty in quantifying such projected amounts, on a forward-looking basis.

  • Capital expenditures are projected as follows (in millions):

2022

Guidance
Total

$

500

to

$

600

  • Net cash provided by operating activities are projected as follows (in millions):
 

2022

Guidance
Total

$

900

to

$

1,050

 
  • Diluted weighted-average shares outstanding are projected to be approximately 133 million to 134 million for 2022.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties. All statements in this press release other than statements of historical fact, including statements regarding projections, expected operating results, and other events that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “thinks,” and similar expressions, are forward-looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. A number of factors could affect the future results of the Company or the healthcare industry generally and could cause the Company’s expected results to differ materially from those expressed in this press release.

These factors include, among other things:

  • developments related to COVID-19, including, without limitation, related to the length and severity of the pandemic; the volume of canceled or rescheduled procedures; the volume of COVID-19 patients cared for across our health systems; the timing, availability and acceptance of effective medical treatments, vaccines (including additional dosages of vaccines) and tests; the spread of potentially more contagious and/or virulent forms of the virus, including variants of the virus for which currently available vaccines, treatments and tests may not be effective or authorized; measures we are taking to respond to the COVID-19 pandemic; the impact of government actions on us, including with respect to vaccine mandates, testing requirements, travel restrictions and other virus containment measures; changes in net operating revenues due to patient volumes, payor mix and evolving macroeconomic conditions; inflationary conditions and increased expenses related to labor, supply chain, capital and other expenditures; workforce disruptions; and supply shortages and disruptions;
  • uncertainty regarding the magnitude and timing of any future payments or benefits we may receive or realize under the Coronavirus Aid, Relief and Economic Security Act (the CARES Act), the Paycheck Protection Program and Health Care Enhancement Act (the PPPHCE Act), the Consolidated Appropriations Act, 2021 (the CAA), the American Rescue Plan Act of 2021 (the ARPA) and any other future stimulus measures related to COVID-19;
  • general economic and business conditions, both nationally and in the regions in which we operate, including economic and business conditions resulting from the COVID-19 pandemic;
  • the impact of current or future federal and state health reform initiatives, including the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the “Affordable Care Act”), and the potential for changes to the Affordable Care Act, its implementation or its interpretation (including through executive orders and court challenges);
  • the extent to and manner in which states support increases, decreases or changes in Medicaid programs, implement health insurance exchanges or alter the provision of healthcare to state residents through legislation, regulation or otherwise;
  • the future and long-term viability of health insurance exchanges and potential changes to the beneficiary enrollment process;
  • risks associated with our substantial indebtedness, leverage and debt service obligations, including our ability to refinance such indebtedness on acceptable terms or to incur additional indebtedness, and our ability to remain in compliance with debt covenants;
  • demographic changes;
  • changes in, or the failure to comply with, federal, state or local laws or governmental regulations affecting our business, including any such laws or governmental regulations which are adopted in connection with the COVID-19 pandemic;
  • potential adverse impact of known and unknown legal, regulatory and governmental proceedings and other loss contingencies, including governmental investigations and audits, and federal and state false claims act litigation;
  • our ability, where appropriate, to enter into and maintain provider arrangements with payors and the terms of these arrangements, which may be further affected by the increasing consolidation of health insurers and managed care companies and vertical integration efforts involving payors and healthcare providers;
  • changes in, or the failure to comply with, contract terms with payors and changes in reimbursement policies or rates paid by federal or state healthcare programs or commercial payors;
  • any security breaches, cyber-attacks, loss of data, other cybersecurity threats or incidents, and any actual or perceived failures to comply with legal requirements governing the privacy and security of health information or other regulated, sensitive or confidential information, or legal requirements regarding data privacy or data protection;
  • any potential impairments in the carrying value of goodwill, other intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets;
  • changes in inpatient or outpatient Medicare and Medicaid payment levels and methodologies;
  • the effects related to the implementation of the sequestration spending reductions pursuant to both the Budget Control Act of 2011 and the Pay-As-You-Go Act of 2010 and the potential for future deficit reduction legislation;
  • increases in the amount and risk of collectability of patient accounts receivable, including decreases in collectability which may result from, among other things, self-pay growth and difficulties in recovering payments for which patients are responsible, including co-pays and deductibles;
  • the efforts of insurers, healthcare providers, large employer groups and others to contain healthcare costs, including the trend toward value-based purchasing;
  • the impact of competitive labor market conditions and the shortage of experienced nurses, including in connection with our ability to hire and retain qualified nurses, physicians, other medical personnel and key management, and increased labor expenses as a result of such competitive labor market conditions, inflation and competition for such positions;
  • any failure to obtain medical supplies or pharmaceuticals at favorable prices;
  • liabilities and other claims asserted against us, including self-insured malpractice claims;
  • competition;
  • trends toward treatment of patients in less acute or specialty healthcare settings, including ambulatory surgery centers or specialty hospitals or via telehealth;
  • changes in medical or other technology;
  • changes in U.S. GAAP;
  • the availability and terms of capital to fund any additional acquisitions or replacement facilities or other capital expenditures;
  • our ability to successfully make acquisitions or complete divestitures, our ability to complete any such acquisitions or divestitures on desired terms or at all, the timing of the completion of any such acquisitions or divestitures, and our ability to realize the intended benefits from any such acquisitions or divestitures;
  • the impact that changes in our relationships with joint venture or syndication partners could have on effectively operating our hospitals or ancillary services or in advancing strategic opportunities;
  • our ability to successfully integrate any acquired hospitals and/or outpatient facilities, or to recognize expected synergies from acquisitions;
  • the impact of seasonal severe weather conditions and climate change, as well as the timing and amount of insurance recoveries in relation to severe weather events;
  • our ability to obtain adequate levels of insurance, including general liability, professional liability, and directors and officers liability insurance;
  • timeliness of reimbursement payments received under government programs;
  • effects related to pandemics, epidemics, or outbreaks of infectious diseases, including the novel coronavirus causing the disease known as COVID-19;
  • any failure to comply with our obligations under license or technology agreements;
  • challenging economic conditions in certain non-urban communities in which we operate;
  • any developments with respect to the final auditing and reporting requirements of, or other adverse developments with respect to, the Corporate Integrity Agreement to which we are subject;
  • the concentration of our revenue in a small number of states;
  • our ability to realize anticipated cost savings and other benefits from our current strategic and operational cost savings initiatives;
  • any changes in or interpretations of income tax laws and regulations; and
  • the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 17, 2022, and other public filings with the Securities and Exchange Commission.

The consolidated operating results for the three months ended March 31, 2022, are not necessarily indicative of the results that may be experienced for any future periods. The Company cautions that the projections for calendar year 2022 set forth in this press release are given as of the date hereof based on currently available information. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

link

Leave a Reply

Your email address will not be published.